The EMPA-KIDNEY clinical trial of Jardiance (empagliflozin) for adults with chronic kidney disease (CKD) was deemed successful enough to stop early by the trial’s Independent Data Monitoring Committee, according to an announcement from Boehringer Ingelheim.
“As the largest SGLT2 inhibitor trial in CKD to date, EMPA-KIDNEY is evaluating the efficacy and safety of empagliflozin in adults with CKD who are frequently seen in clinical practice but who have been under-represented in previous SGLT2 inhibitor trials, therefore addressing a critical unmet need,” the statement said.
“We are thrilled that the trial has shown that empagliflozin is beneficial among the patients studied in EMPA-KIDNEY,” said Professor Richard Haynes, co-Principal Investigator. “We are very grateful to all of the participants who have made this trial possible and look forward to sharing detailed trial results later this year.”
The complete data of the EMPA-KIDNEY trial will be presented at a medical congress.
Read the full report here.
